Navigation Links
FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
Date:5/6/2011

MANHATTAN BEACH, Calif., May 6, 2011 /PRNewswire/ -- Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors.  Neuroendocrine tumors make up less than five percent of all pancreatic cancer diagnoses and are generally slower growing and less aggressive than the more common form of pancreatic cancer, pancreatic adenocarcinoma.

(Logo:  http://photos.prnewswire.com/prnh/20100914/MM64269)

"The FDA approval of Afinitor to treat pancreatic neuroendocrine tumors is welcome news for the pancreatic cancer community. For decades, treatment options for this insidious disease have been limited.  We are thrilled that patients with pancreatic neuroendocrine tumors now have another option when planning their course of treatment," stated Julie Fleshman, President and CEO of the Pancreatic Cancer Action Network.  

Afinitor® underwent rigorous clinical trials to determine the safety and effectiveness of the drug in this specific cancer type.  It was previously approved to treat other cancer types, but needed to prove effective in patients with pancreatic neuroendocrine tumors.  To this point, treatment options for pancreatic neuroendocrine tumors have not been well-established.  Patients have historically been treated with surgery, chemotherapies, and/or radiation.  In contrast to these treatment modalities, Afinitor® is a targeted therapy designed to attack specific proteins that are necessary for the growth of cancer cells.

"The Pancreatic Cancer Action Network encourages all patients to consider clinical trials when exploring treatment options. Clinical trials are a vital part of the research process and development of effective treatment options that will increase the survival rate of pancreatic cancer patients," added Fleshman.

To learn more about pancreatic neuroendocrine tumors and the Pancreatic Cancer Action Network, visit www.pancan.org.

About the Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase the survival rate for people diagnosed with this devastating disease through a bold initiative—The Vision of Progress: Double the Pancreatic Cancer Survival Rate by 2020. Together, we can know, fight and end pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics, better treatments and increase chances of survival.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Julie Fleshman

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=75525


'/>"/>
SOURCE Pancreatic Cancer Action Network
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):